Primary Coenzyme Q10 Deficiency

🏷

Classifications

Harrison's Chapter

Mechanistic Nosology

👪

Inheritance

1

Autosomal Recessive HP:0000007

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:37627647 SUPPORT Human Clinical

"Primary CoQ10 deficiency results from mutations in genes involved in the CoQ10 biosynthetic pathway."

Primary CoQ10 deficiency is caused by biallelic pathogenic variants in CoQ10 biosynthesis genes, inherited in an autosomal recessive pattern.

◆

Subtypes

9

COQ2-related (CoQ10 deficiency-1)

COQ2 hgnc:25223 Autosomal recessive inheritance

COQ2 (4-hydroxybenzoate polyprenyltransferase) was the first CoQ10 biosynthesis gene linked to disease. The phenotype spans infantile multisystem encephalomyopathy with nephrotic syndrome to isolated steroid-resistant nephropathy.

Show evidence (1 reference)

PMID:17186472 SUPPORT Human Clinical

"The first defect in a CoQ(10) biosynthetic gene, COQ2, was identified in a child with encephalomyopathy and nephrotic syndrome and in a younger sibling with only nephropathy."

COQ2 was the first identified primary CoQ10 biosynthesis gene, causing encephalomyopathy with nephrotic syndrome.

COQ4-related (lethal neonatal encephalomyopathy)

COQ4 hgnc:19693 Autosomal recessive inheritance

COQ4 variants cause an autosomal recessive lethal neonatal mitochondrial encephalomyopathy with hypotonia, encephalopathy, seizures, cerebellar atrophy, cardiomyopathy, and lactic acidosis; a founder mutation occurs in the Ashkenazi Jewish population, and a high incidence is reported in southern China.

Show evidence (1 reference)

PMID:26185144 SUPPORT Human Clinical

"Mutations in COQ4 cause an autosomal recessive lethal neonatal mitochondrial encephalomyopathy associated with a founder mutation in the Ashkenazi Jewish population."

COQ4 variants produce a severe lethal neonatal encephalomyopathy form of primary CoQ10 deficiency.

COQ6-related (SRNS with sensorineural deafness)

COQ6 hgnc:20233 Autosomal recessive inheritance

COQ6 (CoQ10 biosynthesis monooxygenase 6) mutations produce early-onset steroid-resistant nephrotic syndrome with sensorineural deafness, an oto-renal phenotype reflecting COQ6 expression in podocytes and inner-ear stria vascularis.

Show evidence (1 reference)

PMID:21540551 SUPPORT Human Clinical

"Each mutation was linked to early-onset SRNS with sensorineural deafness."

COQ6 mutations cause steroid-resistant nephrotic syndrome with sensorineural deafness.

COQ8A/ADCK3-related (cerebellar ataxia)

COQ8A hgnc:16812 Autosomal recessive inheritance

The COQ8A (ADCK3) cerebellar-ataxia form (primary CoQ10 deficiency-4, ARCA2/SCAR9) is curated as a separate dismech entry (Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency). It is cross-referenced here as an already-split member and is not duplicated in this umbrella entry.

Show evidence (1 reference)

PMID:36978966 SUPPORT Human Clinical

"Thus far, 11 disease genes are known (PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9 and HPDL)."

COQ8A is one of the recognized primary CoQ10 biosynthesis disease genes; its cerebellar-ataxia form is curated in a dedicated dismech entry.

COQ8B/ADCK4-related (SRNS)

COQ8B hgnc:19041 Autosomal recessive inheritance

COQ8B (ADCK4) mutations cause steroid-resistant nephrotic syndrome, typically with later (childhood/adolescent) onset than COQ6, and may be partially responsive to CoQ10 supplementation.

Show evidence (1 reference)

PMID:24270420 SUPPORT Human Clinical

"Here, using a combination of homozygosity mapping and whole human exome resequencing, we identified mutations in the aarF domain containing kinase 4 (ADCK4) gene in 15 individuals with SRNS from 8 unrelated families."

COQ8B/ADCK4 mutations cause steroid-resistant nephrotic syndrome through disrupted CoQ10 biosynthesis.

COQ7-related

COQ7 hgnc:2244 Autosomal recessive inheritance

COQ7 (a CoQ10 biosynthesis hydroxylase) deficiency is a rarer form associated with multisystem mitochondrial disease.

Show evidence (1 reference)

PMID:36978966 SUPPORT Human Clinical

"Thus far, 11 disease genes are known (PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9 and HPDL)."

COQ7 is one of the recognized primary CoQ10 biosynthesis disease genes.

COQ9-related (neonatal encephalomyopathy)

COQ9 hgnc:25302 Autosomal recessive inheritance

COQ9 deficiency causes a severe neonatal-onset encephalomyopathy; the Coq9 knockout mouse recapitulates encephalopathy with cerebral gliosis and spongiosis.

Show evidence (1 reference)

PMID:36978966 SUPPORT Human Clinical

"Thus far, 11 disease genes are known (PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9 and HPDL)."

COQ9 is one of the recognized primary CoQ10 biosynthesis disease genes.

PDSS1-related

PDSS1 hgnc:17759 Autosomal recessive inheritance

PDSS1 encodes a subunit of decaprenyl diphosphate synthase, the first enzyme of the CoQ10 biosynthetic pathway responsible for assembly of the polyisoprenoid side chain.

Show evidence (1 reference)

PMID:36978966 SUPPORT Human Clinical

"Only three enzymes (PDSS1, PDSS2 and COQ2) are required for assembly and attachment of the polyisoprenoid side chain."

PDSS1 is one of the three enzymes required for assembly of the polyisoprenoid side chain in CoQ10 biosynthesis.

PDSS2-related (Leigh syndrome with nephropathy)

PDSS2 hgnc:23041 Autosomal recessive inheritance

PDSS2 encodes a subunit of decaprenyl diphosphate synthase, the first enzyme of CoQ10 biosynthesis. Pathogenic variants cause severe Leigh syndrome with nephrotic syndrome and CoQ10 deficiency in muscle and fibroblasts.

Show evidence (1 reference)

PMID:17186472 SUPPORT Human Clinical

"Here, we describe an infant with severe Leigh syndrome, nephrotic syndrome, and CoQ(10) deficiency in muscle and fibroblasts and compound heterozygous mutations in the PDSS2 gene, which encodes a subunit of decaprenyl diphosphate synthase, the first enzyme of the CoQ(10) biosynthetic pathway."

PDSS2 mutations cause Leigh syndrome with nephropathy and CoQ10 deficiency.

⚙

Pathophysiology

3

Defective CoQ10 Biosynthesis

Biallelic pathogenic variants in any of the nuclear CoQ10 biosynthesis genes (PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9) reduce endogenous CoQ10 production, lowering tissue and cellular CoQ10 levels. This is the shared upstream lesion across all primary CoQ10 deficiency subtypes.

ubiquinone biosynthetic process GO:0006744 ↓ DECREASED

Downstream

Impaired Respiratory Chain Electron Transport Reduced CoQ10 impairs electron transfer in the respiratory chain.

Show evidence (1 reference)

PMID:37627647 SUPPORT Human Clinical

"In man, at least 10 genes are required for the biosynthesis of functional CoQ10, a mutation in any one of which can result in a deficit in CoQ10 status."

Defects in any of the CoQ10 biosynthesis genes reduce functional CoQ10, the shared upstream defect.

Impaired Respiratory Chain Electron Transport

CoQ10 normally shuttles electrons from respiratory chain complexes I and II to complex III. Reduced CoQ10 impairs this electron transfer, decreasing oxidative phosphorylation and ATP synthesis, biochemically detectable as reduced combined complex I+III and II+III activities.

respiratory electron transport chain GO:0022904 ↓ DECREASED oxidative phosphorylation GO:0006119 ↓ DECREASED

Downstream

Loss of Antioxidant Defense and Multisystem Energy Failure Energy failure combined with loss of CoQ10 antioxidant and redox functions drives multisystem injury.

Show evidence (1 reference)

PMID:17186472 SUPPORT Human Clinical

"Coenzyme Q(10) (CoQ(10)) is a vital lipophilic molecule that transfers electrons from mitochondrial respiratory chain complexes I and II to complex III."

CoQ10 transfers electrons from complexes I and II to complex III; its deficiency impairs respiratory electron transport.

Loss of Antioxidant Defense and Multisystem Energy Failure

Beyond bioenergetics, CoQ10 is a lipid-soluble antioxidant and supports redox homeostasis, ferroptosis defense, and sulfide oxidation. Combined energy failure and loss of antioxidant/redox protection produce multisystem injury, with the nervous system, kidney, heart, and sensory organs particularly vulnerable. Neurologic injury involves neuronal death, neuroinflammation, and cerebral gliosis.

neuron CL:0000540 podocyte CL:0000653

response to oxidative stress GO:0006979 ↑ INCREASED ferroptosis GO:0097707 ↑ INCREASED

Show evidence (2 references)

PMID:36978966 SUPPORT Human Clinical

"CoQ10 deficiency exerts detrimental effects on the nervous system. Potential consequences are neuronal death, neuroinflammation and cerebral gliosis."

CoQ10 deficiency causes neuronal death, neuroinflammation, and gliosis as downstream tissue injury.

PMID:36978966 SUPPORT Human Clinical

"However, there are many other cellular pathways that also depend on the CoQ10 supply (redox homeostasis, ferroptosis and sulfide oxidation)."

Non-bioenergetic CoQ10-dependent pathways (redox homeostasis, ferroptosis defense, sulfide oxidation) are also disrupted.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

8

Cardiovascular 1

Cardiomyopathy Cardiomyopathy HP:0001638

Show evidence (1 reference)

PMID:26185144 SUPPORT Human Clinical

"cardiomyopathy (5/6)"

Cardiomyopathy was present in 5 of 6 neonatal COQ4 patients.

Ear 1

Sensorineural hearing impairment Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

PMID:21540551 SUPPORT Human Clinical

"In rats, COQ6 was located within cell processes and the Golgi apparatus of renal glomerular podocytes and in stria vascularis cells of the inner ear, consistent with an oto-renal disease phenotype."

COQ6 expression in inner-ear stria vascularis underlies the sensorineural deafness of the oto-renal phenotype.

Musculoskeletal 1

Hypotonia Hypotonia HP:0001252

Show evidence (1 reference)

PMID:26185144 SUPPORT Human Clinical

"Clinical findings included hypotonia (6/6)"

Hypotonia was present in all six neonatal COQ4 patients in this cohort.

Nervous System 3

Encephalopathy Encephalopathy HP:0001298

Show evidence (1 reference)

PMID:36978966 SUPPORT Human Clinical

"Clinical features include encephalopathy, regression, movement disorders, epilepsy and intellectual disability."

Encephalopathy is a recognized core neurologic feature of CoQ10 deficiency.

Seizures Seizure HP:0001250

Show evidence (1 reference)

PMID:36978966 SUPPORT Human Clinical

"Clinical features include encephalopathy, regression, movement disorders, epilepsy and intellectual disability."

Epilepsy/seizures are recognized neurologic features.

Cerebellar atrophy Cerebellar atrophy HP:0001272

Show evidence (1 reference)

PMID:26185144 SUPPORT Human Clinical

"cerebellar atrophy (4/5)"

Cerebellar atrophy was present in 4 of 5 neonatal COQ4 patients with imaging.

Other 2

Nephrotic syndrome Nephrotic syndrome HP:0000100

Show evidence (1 reference)

PMID:21540551 SUPPORT Human Clinical

"Each mutation was linked to early-onset SRNS with sensorineural deafness."

Steroid-resistant nephrotic syndrome is a key renal manifestation, shown here for COQ6.

Lactic acidosis Increased circulating lactate concentration HP:0002151

Show evidence (1 reference)

PMID:39398416 SUPPORT Human Clinical

"Hyperlactatemia was one of the most common manifestations, accounting for 75% of cases (18/24)."

Hyperlactatemia was among the most common manifestations in neonatal COQ4 disease (18/24).

💊

Medical Actions

2

Coenzyme Q10 supplementation

Action: coenzyme Q10 supplementation MAXO:0010012

Agent: coenzyme Q10 CHEBI:46245

High-dose oral CoQ10 (ubiquinone/ubiquinol) supplementation is the only disease-directed therapy. Early treatment can reverse or prevent renal disease (around 30 mg/kg/day) and ameliorate neurologic features (up to 70 mg/kg/day); benefit is limited once irreversible organ injury is established, and severe neonatal forms often respond poorly.

Show evidence (2 references)

PMID:39601013 SUPPORT Human Clinical

"We also demonstrate that early diagnosis and treatment of CoQ10 deficiency with oral supplementation (30 mg/kg/d) can reverse renal manifestations and can completely prevent kidney disease over 10 years of follow-up."

Early high-dose oral CoQ10 can reverse and prevent renal disease.

PMID:39601013 SUPPORT Human Clinical

"We show that oral doses of CoQ10 up to 70 mg/kg/d were needed to ameliorate neurologic features."

Higher doses (up to 70 mg/kg/day) were required to ameliorate neurologic features.

Idebenone

Action: Pharmacotherapy NCIT:C15986

Agent: idebenone CHEBI:31687

Idebenone, a synthetic CoQ10 analogue, was used as an adjunct to control seizures in some patients (10-20 mg/kg/day).

Show evidence (1 reference)

PMID:39601013 SUPPORT Human Clinical

"Additional idebenone was required to control seizures in some cases, and 3 children with neonatal-onset neurologic disease died in early childhood despite receiving high-dose oral CoQ10 from birth."

Idebenone was used as an adjunct to control seizures in some patients.

🔬

Biochemical Markers

1

Reduced muscle CoQ10 and respiratory chain activity

{ }

Source YAML

click to show

name: Primary Coenzyme Q10 Deficiency
creation_date: "2026-06-17T00:00:00Z"
category: Metabolic Disorder
parents:
- Mendelian Disorder
- Metabolic Disorder
- Mitochondrial Disorder
disease_term:
  preferred_term: primary coenzyme Q10 deficiency
  term:
    id: MONDO:0018151
    label: coenzyme Q10 deficiency
description: >-
  Primary coenzyme Q10 (CoQ10, ubiquinone) deficiency is a clinically and
  genetically heterogeneous group of autosomal recessive mitochondrial
  disorders caused by biallelic pathogenic variants in nuclear genes required
  for endogenous CoQ10 biosynthesis. Reduced tissue CoQ10 impairs electron
  transfer through the mitochondrial respiratory chain (between complexes I/II
  and complex III), compromises oxidative phosphorylation, and disrupts
  additional CoQ-dependent processes (antioxidant defense, pyrimidine and
  sulfide metabolism, ferroptosis protection), producing multisystem,
  high-energy-organ disease. Phenotypes range from lethal neonatal
  encephalomyopathy to childhood/adult-onset cerebellar ataxia, with prominent
  renal (steroid-resistant nephrotic syndrome), neurologic, cardiac, and
  sensorineural manifestations that vary by causal gene. It is one of the few
  potentially treatable mitochondrial disorders: high-dose oral CoQ10
  supplementation can reverse or prevent renal disease and ameliorate
  neurologic features if given before irreversible organ injury.
synonyms:
- primary CoQ10 deficiency
- primary ubiquinone deficiency
- coenzyme Q10 biosynthesis deficiency
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:37627647
    reference_title: "Primary Coenzyme Q10 Deficiency: An Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary CoQ10 deficiency results from mutations in genes involved in the
      CoQ10 biosynthetic pathway.
    explanation: >-
      Primary CoQ10 deficiency is caused by biallelic pathogenic variants in
      CoQ10 biosynthesis genes, inherited in an autosomal recessive pattern.
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:36978966
      reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The CoQ10 biosynthesis pathway consists of several enzymes, which are
        encoded by the nuclear DNA.
      explanation: >-
        Primary CoQ10 deficiency is a Mendelian (autosomal recessive) inborn
        error of CoQ10 biosynthesis, placing it in Harrison's Genetics Part.
  - classification_value: ENDOCRINOLOGY_METABOLISM
    evidence:
    - reference: PMID:37508007
      reference_title: "Biosynthesis, Deficiency, and Supplementation of Coenzyme Q."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Cells rely on endogenous CoQ biosynthesis, and defects in this
        still-not-completely understood pathway result in primary CoQ
        deficiencies, a group of conditions biochemically characterised by
        decreased tissue CoQ levels, which in turn are linked to functional
        defects.
      explanation: >-
        Primary CoQ10 deficiency is an inborn error of metabolism (a defect of
        the CoQ10 biosynthetic pathway), placing it in Harrison's
        Endocrinology/Metabolism Part.
  mechanistic_category:
  - classification_value: mitochondrial disease
    evidence:
    - reference: PMID:39601013
      reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Disorders of coenzyme Q10 (CoQ10) biosynthesis comprise a group of 11
        clinically and genetically heterogeneous rare primary mitochondrial
        diseases.
      explanation: >-
        Primary CoQ10 deficiency disorders are classified as primary
        mitochondrial diseases.
has_subtypes:
- name: COQ2
  display_name: COQ2-related (CoQ10 deficiency-1)
  description: >-
    COQ2 (4-hydroxybenzoate polyprenyltransferase) was the first CoQ10
    biosynthesis gene linked to disease. The phenotype spans infantile
    multisystem encephalomyopathy with nephrotic syndrome to isolated
    steroid-resistant nephropathy.
  genes:
  - preferred_term: COQ2
    term:
      id: hgnc:25223
      label: COQ2
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:17186472
    reference_title: "Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The first defect in a CoQ(10) biosynthetic gene, COQ2, was identified in a
      child with encephalomyopathy and nephrotic syndrome and in a younger
      sibling with only nephropathy.
    explanation: >-
      COQ2 was the first identified primary CoQ10 biosynthesis gene, causing
      encephalomyopathy with nephrotic syndrome.
- name: COQ4
  display_name: COQ4-related (lethal neonatal encephalomyopathy)
  description: >-
    COQ4 variants cause an autosomal recessive lethal neonatal mitochondrial
    encephalomyopathy with hypotonia, encephalopathy, seizures, cerebellar
    atrophy, cardiomyopathy, and lactic acidosis; a founder mutation occurs in
    the Ashkenazi Jewish population, and a high incidence is reported in
    southern China.
  genes:
  - preferred_term: COQ4
    term:
      id: hgnc:19693
      label: COQ4
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in COQ4 cause an autosomal recessive lethal neonatal
      mitochondrial encephalomyopathy associated with a founder mutation in the
      Ashkenazi Jewish population.
    explanation: >-
      COQ4 variants produce a severe lethal neonatal encephalomyopathy form of
      primary CoQ10 deficiency.
- name: COQ6
  display_name: COQ6-related (SRNS with sensorineural deafness)
  description: >-
    COQ6 (CoQ10 biosynthesis monooxygenase 6) mutations produce early-onset
    steroid-resistant nephrotic syndrome with sensorineural deafness, an
    oto-renal phenotype reflecting COQ6 expression in podocytes and inner-ear
    stria vascularis.
  genes:
  - preferred_term: COQ6
    term:
      id: hgnc:20233
      label: COQ6
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:21540551
    reference_title: "COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Each mutation was linked to early-onset SRNS with sensorineural deafness.
    explanation: >-
      COQ6 mutations cause steroid-resistant nephrotic syndrome with
      sensorineural deafness.
- name: COQ8A
  display_name: COQ8A/ADCK3-related (cerebellar ataxia)
  description: >-
    The COQ8A (ADCK3) cerebellar-ataxia form (primary CoQ10 deficiency-4,
    ARCA2/SCAR9) is curated as a separate dismech entry
    (Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency). It is
    cross-referenced here as an already-split member and is not duplicated in
    this umbrella entry.
  genes:
  - preferred_term: COQ8A
    term:
      id: hgnc:16812
      label: COQ8A
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thus far, 11 disease genes are known (PDSS1, PDSS2, COQ2, COQ4,
      COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9 and HPDL).
    explanation: >-
      COQ8A is one of the recognized primary CoQ10 biosynthesis disease genes;
      its cerebellar-ataxia form is curated in a dedicated dismech entry.
- name: COQ8B
  display_name: COQ8B/ADCK4-related (SRNS)
  description: >-
    COQ8B (ADCK4) mutations cause steroid-resistant nephrotic syndrome,
    typically with later (childhood/adolescent) onset than COQ6, and may be
    partially responsive to CoQ10 supplementation.
  genes:
  - preferred_term: COQ8B
    term:
      id: hgnc:19041
      label: COQ8B
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:24270420
    reference_title: "ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, using a combination of homozygosity mapping and whole human exome
      resequencing, we identified mutations in the aarF domain containing
      kinase 4 (ADCK4) gene in 15 individuals with SRNS from 8 unrelated
      families.
    explanation: >-
      COQ8B/ADCK4 mutations cause steroid-resistant nephrotic syndrome through
      disrupted CoQ10 biosynthesis.
- name: COQ7
  display_name: COQ7-related
  description: >-
    COQ7 (a CoQ10 biosynthesis hydroxylase) deficiency is a rarer form
    associated with multisystem mitochondrial disease.
  genes:
  - preferred_term: COQ7
    term:
      id: hgnc:2244
      label: COQ7
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thus far, 11 disease genes are known (PDSS1, PDSS2, COQ2, COQ4,
      COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9 and HPDL).
    explanation: >-
      COQ7 is one of the recognized primary CoQ10 biosynthesis disease genes.
- name: COQ9
  display_name: COQ9-related (neonatal encephalomyopathy)
  description: >-
    COQ9 deficiency causes a severe neonatal-onset encephalomyopathy; the Coq9
    knockout mouse recapitulates encephalopathy with cerebral gliosis and
    spongiosis.
  genes:
  - preferred_term: COQ9
    term:
      id: hgnc:25302
      label: COQ9
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thus far, 11 disease genes are known (PDSS1, PDSS2, COQ2, COQ4,
      COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9 and HPDL).
    explanation: >-
      COQ9 is one of the recognized primary CoQ10 biosynthesis disease genes.
- name: PDSS1
  display_name: PDSS1-related
  description: >-
    PDSS1 encodes a subunit of decaprenyl diphosphate synthase, the first
    enzyme of the CoQ10 biosynthetic pathway responsible for assembly of the
    polyisoprenoid side chain.
  genes:
  - preferred_term: PDSS1
    term:
      id: hgnc:17759
      label: PDSS1
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Only three enzymes (PDSS1, PDSS2 and COQ2) are required for assembly and
      attachment of the polyisoprenoid side chain.
    explanation: >-
      PDSS1 is one of the three enzymes required for assembly of the
      polyisoprenoid side chain in CoQ10 biosynthesis.
- name: PDSS2
  display_name: PDSS2-related (Leigh syndrome with nephropathy)
  description: >-
    PDSS2 encodes a subunit of decaprenyl diphosphate synthase, the first
    enzyme of CoQ10 biosynthesis. Pathogenic variants cause severe Leigh
    syndrome with nephrotic syndrome and CoQ10 deficiency in muscle and
    fibroblasts.
  genes:
  - preferred_term: PDSS2
    term:
      id: hgnc:23041
      label: PDSS2
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:17186472
    reference_title: "Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we describe an infant with severe Leigh syndrome, nephrotic
      syndrome, and CoQ(10) deficiency in muscle and fibroblasts and compound
      heterozygous mutations in the PDSS2 gene, which encodes a subunit of
      decaprenyl diphosphate synthase, the first enzyme of the CoQ(10)
      biosynthetic pathway.
    explanation: >-
      PDSS2 mutations cause Leigh syndrome with nephropathy and CoQ10
      deficiency.
pathophysiology:
- name: Defective CoQ10 Biosynthesis
  description: >-
    Biallelic pathogenic variants in any of the nuclear CoQ10 biosynthesis
    genes (PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9)
    reduce endogenous CoQ10 production, lowering tissue and cellular CoQ10
    levels. This is the shared upstream lesion across all primary CoQ10
    deficiency subtypes.
  biological_processes:
  - preferred_term: ubiquinone biosynthetic process
    term:
      id: GO:0006744
      label: ubiquinone biosynthetic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: coenzyme Q10
    term:
      id: CHEBI:46245
      label: coenzyme Q10
    modifier: DECREASED
  evidence:
  - reference: PMID:37627647
    reference_title: "Primary Coenzyme Q10 Deficiency: An Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In man, at least 10 genes are required for the biosynthesis of functional
      CoQ10, a mutation in any one of which can result in a deficit in CoQ10
      status.
    explanation: >-
      Defects in any of the CoQ10 biosynthesis genes reduce functional CoQ10,
      the shared upstream defect.
  downstream:
  - target: Impaired Respiratory Chain Electron Transport
    description: Reduced CoQ10 impairs electron transfer in the respiratory chain.
    causal_link_type: DIRECT
- name: Impaired Respiratory Chain Electron Transport
  description: >-
    CoQ10 normally shuttles electrons from respiratory chain complexes I and II
    to complex III. Reduced CoQ10 impairs this electron transfer, decreasing
    oxidative phosphorylation and ATP synthesis, biochemically detectable as
    reduced combined complex I+III and II+III activities.
  biological_processes:
  - preferred_term: respiratory electron transport chain
    term:
      id: GO:0022904
      label: respiratory electron transport chain
    modifier: DECREASED
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  evidence:
  - reference: PMID:17186472
    reference_title: "Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Coenzyme Q(10) (CoQ(10)) is a vital lipophilic molecule that transfers
      electrons from mitochondrial respiratory chain complexes I and II to
      complex III.
    explanation: >-
      CoQ10 transfers electrons from complexes I and II to complex III; its
      deficiency impairs respiratory electron transport.
  downstream:
  - target: Loss of Antioxidant Defense and Multisystem Energy Failure
    description: >-
      Energy failure combined with loss of CoQ10 antioxidant and redox
      functions drives multisystem injury.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Loss of Antioxidant Defense and Multisystem Energy Failure
  description: >-
    Beyond bioenergetics, CoQ10 is a lipid-soluble antioxidant and supports
    redox homeostasis, ferroptosis defense, and sulfide oxidation. Combined
    energy failure and loss of antioxidant/redox protection produce multisystem
    injury, with the nervous system, kidney, heart, and sensory organs
    particularly vulnerable. Neurologic injury involves neuronal death,
    neuroinflammation, and cerebral gliosis.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: podocyte
    term:
      id: CL:0000653
      label: podocyte
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  - preferred_term: ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
    modifier: INCREASED
  evidence:
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CoQ10 deficiency exerts detrimental effects on the nervous system.
      Potential consequences are neuronal death, neuroinflammation and cerebral
      gliosis.
    explanation: >-
      CoQ10 deficiency causes neuronal death, neuroinflammation, and gliosis as
      downstream tissue injury.
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, there are many other cellular pathways that also depend on the
      CoQ10 supply (redox homeostasis, ferroptosis and sulfide oxidation).
    explanation: >-
      Non-bioenergetic CoQ10-dependent pathways (redox homeostasis, ferroptosis
      defense, sulfide oxidation) are also disrupted.
phenotypes:
- category: Phenotypic abnormality
  name: Encephalopathy
  description: >-
    Encephalopathy with developmental delay/regression is a core neurologic
    manifestation, especially in neonatal/infantile-onset forms.
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features include encephalopathy, regression, movement disorders,
      epilepsy and intellectual disability.
    explanation: >-
      Encephalopathy is a recognized core neurologic feature of CoQ10
      deficiency.
- category: Phenotypic abnormality
  name: Seizures
  description: Epilepsy/seizures are common, particularly in severe early-onset forms.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features include encephalopathy, regression, movement disorders,
      epilepsy and intellectual disability.
    explanation: Epilepsy/seizures are recognized neurologic features.
- category: Phenotypic abnormality
  name: Hypotonia
  description: Hypotonia is a frequent feature of neonatal-onset COQ4 disease.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings included hypotonia (6/6)"
    explanation: >-
      Hypotonia was present in all six neonatal COQ4 patients in this cohort.
- category: Phenotypic abnormality
  name: Cerebellar atrophy
  description: >-
    Cerebellar atrophy is a characteristic neuroimaging finding, prominent in
    COQ8A ataxia and seen in neonatal COQ4 disease.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar atrophy (4/5)"
    explanation: >-
      Cerebellar atrophy was present in 4 of 5 neonatal COQ4 patients with
      imaging.
- category: Phenotypic abnormality
  name: Nephrotic syndrome
  description: >-
    Steroid-resistant nephrotic syndrome is a major renal manifestation in
    COQ2, COQ6, and COQ8B forms and can progress to end-stage kidney disease.
  phenotype_term:
    preferred_term: Steroid-resistant nephrotic syndrome
    term:
      id: HP:0000100
      label: Nephrotic syndrome
  evidence:
  - reference: PMID:21540551
    reference_title: "COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Each mutation was linked to early-onset SRNS with sensorineural deafness.
    explanation: >-
      Steroid-resistant nephrotic syndrome is a key renal manifestation, shown
      here for COQ6.
- category: Phenotypic abnormality
  name: Sensorineural hearing impairment
  description: >-
    Sensorineural deafness accompanies nephrotic syndrome in the COQ6 oto-renal
    form, reflecting COQ6 expression in inner-ear stria vascularis cells.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:21540551
    reference_title: "COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In rats, COQ6 was located within cell processes and the Golgi apparatus
      of renal glomerular podocytes and in stria vascularis cells of the inner
      ear, consistent with an oto-renal disease phenotype.
    explanation: >-
      COQ6 expression in inner-ear stria vascularis underlies the sensorineural
      deafness of the oto-renal phenotype.
- category: Phenotypic abnormality
  name: Cardiomyopathy
  description: Cardiomyopathy occurs notably in neonatal COQ4 disease.
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cardiomyopathy (5/6)"
    explanation: Cardiomyopathy was present in 5 of 6 neonatal COQ4 patients.
- category: Phenotypic abnormality
  name: Lactic acidosis
  description: >-
    Hyperlactatemia/lactic acidosis is a common metabolic marker of impaired
    oxidative phosphorylation.
  phenotype_term:
    preferred_term: Increased circulating lactate concentration
    term:
      id: HP:0002151
      label: Increased circulating lactate concentration
  evidence:
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hyperlactatemia was one of the most common manifestations, accounting for
      75% of cases (18/24).
    explanation: >-
      Hyperlactatemia was among the most common manifestations in neonatal COQ4
      disease (18/24).
diagnosis:
- name: Molecular genetic testing
  description: >-
    Genome-wide molecular testing (WES/WGS or multigene panels) is the
    recommended first-line diagnostic approach because there are no
    pathognomonic blood, muscle, or imaging biomarkers and because early
    diagnosis enables potentially disease-modifying treatment.
  results: >-
    Detection of biallelic pathogenic variants in a CoQ10 biosynthesis gene
    confirms the molecular diagnosis and guides treatment.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An early genome-wide diagnostic approach is needed for expeditious
      diagnosis of CoQ10 biosynthesis disorder because our study demonstrates
      that there are no pathognomonic blood, muscle, or imaging biomarkers of
      these diseases.
    explanation: >-
      Genome-wide molecular testing is recommended because no pathognomonic
      biomarkers exist.
biochemical:
- name: Reduced muscle CoQ10 and respiratory chain activity
  notes: >-
    Biochemical support includes reduced CoQ10 levels in skeletal muscle and
    reduced combined activities of respiratory chain complexes I+III and II+III
    on muscle homogenates; plasma CoQ10 is not diagnostically reliable.
treatments:
- name: Coenzyme Q10 supplementation
  description: >-
    High-dose oral CoQ10 (ubiquinone/ubiquinol) supplementation is the only
    disease-directed therapy. Early treatment can reverse or prevent renal
    disease (around 30 mg/kg/day) and ameliorate neurologic features (up to
    70 mg/kg/day); benefit is limited once irreversible organ injury is
    established, and severe neonatal forms often respond poorly.
  treatment_term:
    preferred_term: coenzyme Q10 supplementation
    term:
      id: MAXO:0010012
      label: coenzyme Q10 supplementation
    therapeutic_agent:
    - preferred_term: coenzyme Q10
      term:
        id: CHEBI:46245
        label: coenzyme Q10
  evidence:
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We also demonstrate that early diagnosis and treatment of CoQ10
      deficiency with oral supplementation (30 mg/kg/d) can reverse renal
      manifestations and can completely prevent kidney disease over 10 years of
      follow-up.
    explanation: Early high-dose oral CoQ10 can reverse and prevent renal disease.
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We show that oral doses of CoQ10 up to 70 mg/kg/d were needed to
      ameliorate neurologic features.
    explanation: >-
      Higher doses (up to 70 mg/kg/day) were required to ameliorate neurologic
      features.
- name: Idebenone
  description: >-
    Idebenone, a synthetic CoQ10 analogue, was used as an adjunct to control
    seizures in some patients (10-20 mg/kg/day).
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: idebenone
      term:
        id: CHEBI:31687
        label: idebenone
  evidence:
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional idebenone was required to control seizures in some cases, and
      3 children with neonatal-onset neurologic disease died in early childhood
      despite receiving high-dose oral CoQ10 from birth.
    explanation: Idebenone was used as an adjunct to control seizures in some patients.
prevalence:
- population: General population
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_high: 1.0
  percentage: <0.001%
  notes: >-
    Primary CoQ10 deficiency is very rare, with prevalence/incidence estimated
    at less than 1 per 100,000 population.
progression:
- phase: Neonatal/infantile severe multisystem disease
  age_range: Neonatal to infantile onset
  evidence:
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional idebenone was required to control seizures in some cases, and
      3 children with neonatal-onset neurologic disease died in early childhood
      despite receiving high-dose oral CoQ10 from birth.
    explanation: >-
      Neonatal-onset neurologic disease has poor outcomes even with early
      high-dose CoQ10.
animal_models:
- species: Mouse
  genotype: Coq9 knockout
  description: >-
    The Coq9 knockout mouse recapitulates encephalopathy with cerebral gliosis
    and spongiosis, modeling the neurologic injury of CoQ10 deficiency.
  associated_phenotypes:
  - Encephalopathy
  - Cerebral gliosis
  evidence:
  - reference: PMID:36978966
    reference_title: "Neuroimaging in Primary Coenzyme-Q(10)-Deficiency Disorders."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      CoQ10 deficiency exerts detrimental effects on the nervous system.
      Potential consequences are neuronal death, neuroinflammation and cerebral
      gliosis.
    explanation: >-
      Model and human evidence converge on neuronal death, neuroinflammation,
      and cerebral gliosis as consequences of CoQ10 deficiency.
clinical_trials: []
datasets: []
notes: >-
  This is the umbrella entry for primary (biosynthesis) coenzyme Q10 deficiency.
  The COQ8A/ADCK3 cerebellar-ataxia form is curated separately as
  Autosomal_Recessive_Ataxia_Due_to_Ubiquinone_Deficiency and is
  cross-referenced here (has_subtypes: COQ8A) rather than duplicated. COQ5 and
  HPDL are additional reported CoQ10-biosynthesis disease genes but are not yet
  given dedicated subtype blocks pending citable gene-specific evidence.

📚

References & Deep Research

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 32 citations 2026-06-17T22:54:18.584964

1. Disease Information

1.1 What is the disease?

Definition (current understanding): GeneReviews (2023) defines the term primary CoQ10 deficiency as “the group of conditions characterized by a reduction of CoQ10 levels in tissues or cultured cells associated with biallelic pathogenic variants in one of the ten genes involved in the biosynthesis of CoQ10.” (salviati2023primarycoenzymeq10b pages 1-3)

Treatability concept: Multiple recent reviews emphasize it is potentially treatable if recognized early, because once critical-organ injury (kidney/CNS) is established, recovery is limited. (mantle2023primarycoenzymeq10 pages 1-2, mantle2024efficacyandsafety pages 2-3)

1.2 Key identifiers

MONDO: MONDO:0018151 (carmody2023themedicalaction pages 5-8)
MAxO treatment mapping: MAXO:0010012 “coenzyme Q10 supplementation”; definition “Addition of coenzyme Q10 to the diet,” input chemical CHEBI:46245 (coenzyme Q10 / coenzyme Q); explicitly stated to treat diseases including MONDO:0018151 (carmody2023themedicalaction pages 5-8)

Not retrieved in tool evidence: OMIM disease number(s), Orphanet ORPHA code, ICD-10/ICD-11, MeSH. These likely exist but were not present in the obtained full-text extracts.

1.3 Synonyms / alternative names

Primary coenzyme Q10 deficiency; primary CoQ10 deficiency; primary ubiquinone deficiency (salviati2023primarycoenzymeq10b pages 1-3)

1.4 Evidence source type

The knowledge base content here is derived from: - Aggregated disease-level syntheses (GeneReviews-style overview and narrative reviews) (salviati2023primarycoenzymeq10b pages 1-3, mantle2023primarycoenzymeq10 pages 1-2) - Human cohort/case-series clinical evidence (single-center cohort of genetically confirmed cases; neonatal COQ4 case series + literature review) (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic cause: PCoQD results from pathogenic variants in nuclear genes encoding CoQ10 biosynthesis proteins; recent sources repeatedly emphasize biallelic pathogenic variants (autosomal recessive pattern). (salviati2023primarycoenzymeq10b pages 1-3, salviati2023primarycoenzymeq10b pages 5-7)

2.2 Risk factors

Genetic: Presence of biallelic pathogenic variants in one of the canonical CoQ10 biosynthesis genes (see below) is causal. (salviati2023primarycoenzymeq10b pages 1-3)
Environmental: No specific environmental risk factors were identified in the retrieved evidence; by definition PCoQD is a primary genetic biosynthesis disorder.

2.3 Protective factors

No validated protective genetic variants or environmental protective exposures were identified in the retrieved evidence.

2.4 Gene–environment interactions

Not specifically described in the retrieved sources.

3. Phenotypes

3.1 Major phenotype domains (with frequencies when available)

PCoQD is clinically heterogeneous, with core involvement of the CNS, kidney, muscle, and heart. (wahedi2024clinicalfeaturesbiochemistry pages 1-2, salviati2023primarycoenzymeq10b pages 3-5)

Neurologic phenotypes - Encephalopathy, developmental delay/regression, movement disorders, epilepsy, intellectual disability (munch2023neuroimaginginprimary pages 1-3) - In a 14-patient genetically confirmed cohort: seizures in 8/14 (wahedi2024clinicalfeaturesbiochemistry pages 2-3)

Renal phenotypes - Steroid-resistant nephrotic syndrome (SRNS) and progression to ESKD are key manifestations in several gene-specific forms; in the 14-patient cohort, SRNS in 3/14. (wahedi2024clinicalfeaturesbiochemistry pages 2-3)

Metabolic / laboratory phenotypes - Hyperlactatemia: 14-patient cohort had lactate elevated in 5/12 tested (wahedi2024clinicalfeaturesbiochemistry pages 2-3) - Neonatal COQ4 series: hyperlactatemia 18/24 (75%) (reported in abstract; paper retrieved but not fully evidence-extracted here beyond cohort stats in artifact) (wahedi2024clinicalfeaturesbiochemistry pages 2-3)

Neuroimaging phenotypes (MRI patterns) MRI is emphasized as central for assessing neurologic injury. The neuroimaging review states: “Brain magnetic resonance imaging (MRI) is the most important tool for diagnostic evaluation of neurological damage in individuals with CoQ10 deficiency.” (munch2023neuroimaginginprimary pages 1-3) - Common patterns across genes: leukoencephalopathy/white matter changes, cerebral/cerebellar atrophy, Leigh-like basal ganglia/brainstem lesions, stroke-like lesions, lactate peaks on MR spectroscopy. (munch2023neuroimaginginprimary pages 3-4, munch2023neuroimaginginprimary pages 10-12) - COQ8A: cerebellar atrophy is reported in 94% of patients summarized (munch2023neuroimaginginprimary pages 6-9)

3.2 Suggested HPO terms (non-exhaustive; evidence-aligned)

(These are ontology suggestions based on the described phenotypes; not explicitly enumerated in the cited papers.) - HP:0001250 Seizures; HP:0001263 Global developmental delay; HP:0001252 Muscular hypotonia; HP:0001251 Ataxia; HP:0001272 Cerebellar atrophy; HP:0004372 Status epilepticus; HP:0001257 Spasticity; HP:0001290 Generalized hypotonia; HP:0003070 Renal insufficiency; HP:0000100 Nephrotic syndrome; HP:0000510 Retinopathy; HP:0000608 Optic atrophy; HP:0001644 Cardiomyopathy.

3.3 Quality of life impact

Direct QoL instrument data (EQ-5D/SF-36/PROMIS) were not located in the retrieved evidence; however, neurological disability (developmental delay, epilepsy, ataxia) and progression to renal failure imply major functional impairment. (salviati2023primarycoenzymeq10b pages 3-5, wahedi2024clinicalfeaturesbiochemistry pages 1-2)

4. Genetic / Molecular Information

4.1 Causal genes (core list)

GeneReviews (2023) emphasizes ten genes; a neuroimaging review includes 11 disease genes (adding HPDL). (salviati2023primarycoenzymeq10b pages 1-3, munch2023neuroimaginginprimary pages 1-3)

Canonical CoQ biosynthesis genes (GeneReviews): - PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9 (salviati2023primarycoenzymeq10b pages 1-3)

Additional disease gene in neuroimaging review: - HPDL (munch2023neuroimaginginprimary pages 1-3)

4.2 Pathogenic variants

Variant-level catalogs (ClinVar allele frequencies; ACMG/AMP classifications per-variant; founder variants) were not extractable from the retrieved evidence chunks. However, the disease mechanism requires biallelic pathogenic variants in the relevant genes. (salviati2023primarycoenzymeq10b pages 5-7)

4.3 Modifier genes / epigenetics / chromosomal abnormalities

Not described in the retrieved sources.

5. Environmental Information

PCoQD is a primary genetic biosynthesis defect; no specific toxins, lifestyle factors, or infectious triggers were supported in the retrieved evidence.

6. Mechanism / Pathophysiology

6.1 Key concepts: CoQ10 functions

Recent reviews stress CoQ10’s roles beyond OXPHOS.

Direct abstract quote (Mantle et al., 2023, Antioxidants; Aug 2023; DOI: https://doi.org/10.3390/antiox12081652): - “Coenzyme Q10 (CoQ10) has a number of vital functions in all cells, both mitochondrial and extra-mitochondrial.” (mantle2023primarycoenzymeq10 pages 1-2)

Neuroimaging review (Mar 2023; DOI: https://doi.org/10.3390/antiox12030718) highlights: - CoQ10’s best-known role is electron transfer/ATP synthesis, but “there are many other cellular pathways that also depend on the CoQ10 supply (redox homeostasis, ferroptosis and sulfide oxidation).” (munch2023neuroimaginginprimary pages 1-3)

Biochemistry review (Jul 2023; DOI: https://doi.org/10.3390/antiox12071469): CoQ is electron acceptor for multiple dehydrogenases (DHODH, ETFDH, SQOR, etc.) and contributes to ferroptosis protection via the FSP1 system. (staiano2023biosynthesisdeficiencyand pages 1-2)

6.2 Causal chain (trigger → molecular dysfunction → tissue injury → clinical phenotype)

Upstream: biallelic pathogenic variants in CoQ biosynthesis genes → reduced CoQ10 in tissues/cultured cells. (salviati2023primarycoenzymeq10b pages 1-3)

Midstream: impaired electron transfer between respiratory chain complexes → impaired oxidative phosphorylation, reduced ATP production (especially affecting high-energy organs), plus disruption of non-bioenergetic CoQ roles (redox homeostasis, ferroptosis defense, sulfide oxidation; dehydrogenase-linked metabolism). (munch2023neuroimaginginprimary pages 1-3, staiano2023biosynthesisdeficiencyand pages 1-2)

Downstream: neurologic injury is conceptualized as involving “neuronal death, neuroinflammation and cerebral gliosis.” (munch2023neuroimaginginprimary pages 1-3)

6.3 Cellular processes and pathways (suggested ontology terms)

Evidence-based processes include: - Oxidative phosphorylation impairment; redox imbalance/oxidative stress; neuroinflammation and gliosis; ferroptosis-related defenses; sulfide oxidation dependence. (munch2023neuroimaginginprimary pages 1-3)

Suggested GO biological process terms (ontology suggestions based on described mechanisms): - GO:0006119 oxidative phosphorylation; GO:0006979 response to oxidative stress; GO:0006954 inflammatory response; GO:0097468 neuronal death; GO:0097034 glial cell activation; GO:0070228 regulation of ferroptosis; GO:1902600 hydrogen sulfide metabolic process.

Suggested CL cell types (ontology suggestions): - CL:0000540 neuron; CL:0000127 astrocyte; CL:0000129 microglial cell; CL:0002301 podocyte (for CoQ nephropathy/SRNS contexts).

7. Anatomical Structures Affected

7.1 Organ systems

Central nervous system (encephalopathy, epilepsy, cerebellar ataxia/atrophy; MRI patterns) (munch2023neuroimaginginprimary pages 1-3, munch2023neuroimaginginprimary pages 6-9)
Kidney (SRNS/ESKD; potentially reversible if treated early in some cases) (wahedi2024clinicalfeaturesbiochemistry pages 1-2)
Heart (cardiomyopathy) (mantle2024efficacyandsafety pages 2-3)
Eye/optic nerve/retina (optic atrophy/retinopathy in subsets) (mantle2024efficacyandsafety pages 2-3)

7.2 Suggested UBERON terms (ontology suggestions)

Cerebellum (UBERON:0002037), brain (UBERON:0000955), kidney (UBERON:0002113), heart (UBERON:0000948), retina (UBERON:0000966), optic nerve (UBERON:0001778).

7.3 Subcellular localization

Primary locus of dysfunction is mitochondrial: CoQ10 is a lipid molecule of cellular membranes with key respiratory chain function. (munch2023neuroimaginginprimary pages 1-3) Suggested GO cellular component: mitochondrion (GO:0005739), inner mitochondrial membrane (GO:0005743).

8. Temporal Development

8.1 Onset

Onset is highly variable (neonatal to adulthood) across CoQ biosynthesis disorders. (munch2023neuroimaginginprimary pages 1-3)

8.2 Progression

GeneReviews summary indicates severe neonatal multisystem disease often has poor outcome, while later-onset cases show better response to high-dose supplementation. (salviati2023primarycoenzymeq10b pages 3-5)

9. Inheritance and Population

9.1 Inheritance

GeneReviews-style text emphasizes biallelic pathogenic variants (autosomal recessive). (salviati2023primarycoenzymeq10b pages 1-3)

9.2 Epidemiology

Recent pediatric-focused review states prevalence/incidence were estimated as “less than 1 per 100,000 population.” (mantle2024efficacyandsafety pages 2-3)

A different review estimated “approximately 120,000 patients worldwide,” but this appears to be a broad estimate rather than registry-derived epidemiology. (mantle2023primarycoenzymeq10 pages 1-2)

9.3 Demographics / geographic distribution

Neonatal COQ4 literature review reported that “Half of the cases are Chinese.” (wahedi2024clinicalfeaturesbiochemistry pages 2-3)

10. Diagnostics

10.1 Biochemical testing

GeneReviews (2023) indicates biochemical testing now has a limited role, used when molecular results are inconclusive or to support VUS interpretation. Key supportive findings include: - “Reduced levels of CoQ10 in skeletal muscle” - “Reduced activities of complex I+III and II+III of the mitochondrial respiratory chain on frozen muscle homogenates” (salviati2023primarycoenzymeq10b pages 5-7)

The same GeneReviews extract states plasma CoQ10 is not diagnostically useful. (salviati2023primarycoenzymeq10b pages 5-7)

A 2024 cohort used high-performance liquid chromatography quantification of CoQ10 in muscle and PBMNCs and respiratory chain enzyme assays. (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

10.2 Genetic testing

Because “there are no pathognomonic blood, muscle, or imaging biomarkers of these diseases,” an “early genome-wide diagnostic approach” is recommended for expeditious diagnosis. (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

In the neonatal COQ4 series, 20/24 were diagnosed by whole exome sequencing. (wahedi2024clinicalfeaturesbiochemistry pages 2-3)

10.3 Imaging

MRI is emphasized as most important for assessing neurologic damage in CoQ10 deficiency. (munch2023neuroimaginginprimary pages 1-3)

10.4 Differential diagnosis

GeneReviews excerpt notes secondary CoQ10 deficiency causes to consider, including respiratory chain defects and multiple acyl-CoA dehydrogenase deficiency. (salviati2023primarycoenzymeq10b pages 5-7)

11. Outcome / Prognosis

11.1 Prognosis statistics (recent)

Neonatal COQ4 mutation series (Frontiers in Pediatrics, Sep 2024; DOI: https://doi.org/10.3389/fped.2024.1410133): - Mortality: Chinese 9/12 (75%) vs other regions 11/12 (91.7%) (P=0.27) - Mean survival time 60.0 ± 98.0 days (95% CI 0–252 days) - CoQ10 treatment: 9/24 received CoQ10, and all 4 surviving patients received CoQ10 supplementation (wahedi2024clinicalfeaturesbiochemistry pages 2-3)

Single-center cohort (Neurology Genetics, Dec 2024; DOI: https://doi.org/10.1212/nxg.0000000000200209): - Despite high-dose CoQ10 from birth, “3 children with neonatal-onset neurologic disease died in early childhood” (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

11.2 Prognostic factors

GeneReviews excerpt indicates severity/onset matters: “Children with severe multisystem CoQ10 deficiency respond poorly to treatment and generally die within the neonatal period or in the first year of life,” whereas “Individuals with later-onset disease show better response to supplementation with high-dose oral CoQ10.” (salviati2023primarycoenzymeq10b pages 3-5)

12. Treatment

12.1 Pharmacotherapy (current standard)

Oral CoQ10 supplementation is consistently described as the principal/only disease-directed therapy in recent reviews.

Direct abstract quote (Mantle & Hargreaves, Apr 2024; DOI: https://doi.org/10.3390/antiox13050530): - “The only treatment for primary CoQ10 deficiency is oral supplementation with CoQ10,” with typical doses in clinical studies “10–30 mg/kg/day.” (mantle2024efficacyandsafety pages 2-3)

Cohort dosing/outcome evidence (Dec 2024 cohort): - “oral doses of CoQ10 up to 70 mg/kg/d were needed to ameliorate neurologic features” (wahedi2024clinicalfeaturesbiochemistry pages 1-2) - “early diagnosis and treatment… (30 mg/kg/d) can reverse renal manifestations and can completely prevent kidney disease over 10 years of follow-up.” (wahedi2024clinicalfeaturesbiochemistry pages 1-2)

Adjunct therapy: - “Additional idebenone was required to control seizures in some cases” with idebenone used at 10–20 mg/kg/day in that cohort. (wahedi2024clinicalfeaturesbiochemistry pages 2-3)

12.2 Treatment monitoring / real-world implementation

PBMNC CoQ10 monitoring can demonstrate absorption and track response; the cohort reported PBMNC increases (examples) of +352%, +146% then +320%, +221% in individual patients. (wahedi2024clinicalfeaturesbiochemistry pages 2-3)

Image-based evidence: Wahedi et al. include tables summarizing patient-level dosing/outcomes and a figure showing serial PBMNC CoQ10 monitoring. (wahedi2024clinicalfeaturesbiochemistry media 455edda8, wahedi2024clinicalfeaturesbiochemistry media 782a63c5, wahedi2024clinicalfeaturesbiochemistry media 84940300)

12.3 Clinical trials landscape

A recent pediatric review notes “no formal clinical trials (randomised controlled or otherwise) have been reported” for primary CoQ10 deficiency treatment. (mantle2024efficacyandsafety pages 2-3)

12.4 Suggested MAXO terms

MAXO:0010012 coenzyme Q10 supplementation (carmody2023themedicalaction pages 5-8)
Additional suggested actions (ontology suggestions): antiseizure therapy; renal transplantation; ACE inhibitor therapy for proteinuria (not fully evidenced in retrieved 2023–2024 texts here).

13. Prevention

Primary prevention is not applicable in the classic public-health sense because PCoQD is inherited.

Secondary/tertiary prevention concept (early detection + early therapy): Multiple sources emphasize early diagnosis and prompt high-dose supplementation to prevent irreversible organ damage. (wahedi2024clinicalfeaturesbiochemistry pages 1-2, mantle2024efficacyandsafety pages 2-3)

Genetic counseling and cascade testing are implied by autosomal recessive inheritance, but explicit guideline text was not retrieved.

14. Other Species / Natural Disease

No naturally occurring veterinary disease analogs were identified in the retrieved evidence.

15. Model Organisms and Experimental Systems

15.1 Yeast and in vitro systems

A diagnostic-methods review states: “Most of the information about the CoQ biosynthesis pathway comes from yeast.” (rodriguezaguilera2017biochemicalassessmentof pages 1-3)

Human fibroblasts are widely used to assess CoQ10 content and functional rescue; the same review notes that “CoQ10 but not other quinones can restore mitochondrial function in deficient human fibroblasts.” (rodriguezaguilera2017biochemicalassessmentof pages 1-3)

15.2 Mouse models (examples explicitly mentioned)

Coq9 knock-out mouse: “showed cerebral gliosis and spongiosis” (munch2023neuroimaginginprimary pages 1-3)
Coq7 deficiency in mice: “induced a microglial metabolic reprogramming” (munch2023neuroimaginginprimary pages 1-3)
Additional models summarized in 2024 mitochondrial disease muscle study: Pdss2 deficiency mouse, Coq7 knockout mice, Coq8a (Adck3) null mouse (slowly progressive cerebellar ataxia), Coq9 knockouts (encephalopathy), and Adck2+/− model (hernandez‐camacho2024prenatalandprogressive pages 1-2)

Recent developments and expert synthesis (2023–2024 emphasis)

Shift toward genome-wide diagnosis: A 2024 cohort argues for early genome-wide testing because there are no pathognomonic biomarkers and because renal disease may be preventable with early treatment. (wahedi2024clinicalfeaturesbiochemistry pages 1-2)
Dose escalation for neurologic benefit: The same cohort reports neurologic improvement sometimes requires up to 70 mg/kg/day, higher than historical “10–30 mg/kg/day” frequently cited in review literature. (wahedi2024clinicalfeaturesbiochemistry pages 1-2, mantle2024efficacyandsafety pages 2-3)
Monitoring via PBMNC CoQ10: Serial PBMNC monitoring is increasingly used to document absorption/biological exposure in real-world clinical management. (wahedi2024clinicalfeaturesbiochemistry pages 2-3, wahedi2024clinicalfeaturesbiochemistry media 455edda8)
Expanded mechanistic framing: Reviews emphasize non-bioenergetic roles (ferroptosis, sulfide oxidation, redox homeostasis), supporting why phenotypic heterogeneity may not be explained by ATP deficiency alone. (munch2023neuroimaginginprimary pages 1-3, staiano2023biosynthesisdeficiencyand pages 1-2)

Limitations of this report (evidence availability)

PMIDs: Many retrieved sources were available with DOI/URL but PMIDs were not present in the extracted text chunks; therefore PMID-level citations could not be systematically provided.
ICD/Orphanet/MeSH/OMIM numbers: Not retrieved in the available evidence extracts; MONDO and MAxO mappings were retrieved and reported. (carmody2023themedicalaction pages 5-8)
Variant catalog details (allele frequencies; ClinVar classifications): Not available in retrieved evidence.

Key URLs (most recent/authoritative in this run)

Wahedi et al., Neurology Genetics (Dec 2024): https://doi.org/10.1212/nxg.0000000000200209 (wahedi2024clinicalfeaturesbiochemistry pages 1-2)
Salviati et al., GeneReviews-style overview (2023): (source text retrieved without a stable GeneReviews URL in evidence) (salviati2023primarycoenzymeq10b pages 1-3)
Mantle et al., Antioxidants (Aug 2023): https://doi.org/10.3390/antiox12081652 (mantle2023primarycoenzymeq10 pages 1-2)
Münch et al., Antioxidants (Mar 2023): https://doi.org/10.3390/antiox12030718 (munch2023neuroimaginginprimary pages 1-3)
Mantle & Hargreaves, Antioxidants (Apr 2024): https://doi.org/10.3390/antiox13050530 (mantle2024efficacyandsafety pages 2-3)
MAxO ontology paper, Med (Dec 2023): https://doi.org/10.1016/j.medj.2023.10.003 (carmody2023themedicalaction pages 5-8)

References

(salviati2023primarycoenzymeq10b pages 1-3): L Salviati, E Trevisson, C Agosto, M Doimo, and P Navas. Primary coenzyme q10 deficiency overview. Unknown journal, 2023.
(carmody2023themedicalaction pages 5-8): Leigh C. Carmody, Michael A. Gargano, Sabrina Toro, Nicole A. Vasilevsky, Margaret P. Adam, Hannah Blau, Lauren E. Chan, David Gomez-Andres, Rita Horvath, Megan L. Kraus, Markus S. Ladewig, David Lewis-Smith, Hanns Lochmüller, Nicolas A. Matentzoglu, Monica C. Munoz-Torres, Catharina Schuetz, Berthold Seitz, Morgan N. Similuk, Teresa N. Sparks, Timmy Strauss, Emilia M. Swietlik, Rachel Thompson, Xingmin Aaron Zhang, Christopher J. Mungall, Melissa A. Haendel, and Peter N. Robinson. The medical action ontology: a tool for annotating and analyzing treatments and clinical management of human disease. Med, 4:913-927.e3, Dec 2023. URL: https://doi.org/10.1016/j.medj.2023.10.003, doi:10.1016/j.medj.2023.10.003. This article has 15 citations and is from a domain leading peer-reviewed journal.
(wahedi2024clinicalfeaturesbiochemistry pages 1-2): Azizia Wahedi, Sniya Sudhakar, Amanda Lam, Jose Ignacio Rodriguez Ciancio, Philippa Mills, Paul Gissen, Alice Gardham, Jogesh Kapadia, Jane Hassell, Simon Heales, and Shamima Rahman. Clinical features, biochemistry, imaging, and treatment response in a single-center cohort with coenzyme q ₁₀ biosynthesis disorders. Dec 2024. URL: https://doi.org/10.1212/nxg.0000000000200209, doi:10.1212/nxg.0000000000200209. This article has 6 citations.
(salviati2023primarycoenzymeq10b pages 3-5): L Salviati, E Trevisson, C Agosto, M Doimo, and P Navas. Primary coenzyme q10 deficiency overview. Unknown journal, 2023.
(mantle2023primarycoenzymeq10 pages 1-2): David Mantle, Lauren Millichap, Jesus Castro-Marrero, and Iain P. Hargreaves. Primary coenzyme q10 deficiency: an update. Antioxidants, 12:1652, Aug 2023. URL: https://doi.org/10.3390/antiox12081652, doi:10.3390/antiox12081652. This article has 51 citations.
(mantle2024efficacyandsafety pages 2-3): David Mantle and Iain Parry Hargreaves. Efficacy and safety of coenzyme q10 supplementation in neonates, infants and children: an overview. Antioxidants, 13:530, Apr 2024. URL: https://doi.org/10.3390/antiox13050530, doi:10.3390/antiox13050530. This article has 14 citations.
(munch2023neuroimaginginprimary pages 1-3): Juliane Münch, Jannik Prasuhn, Lucia Laugwitz, Cheuk-Wing Fung, Brian H.-Y. Chung, Marcello Bellusci, Ertan Mayatepek, Dirk Klee, and Felix Distelmaier. Neuroimaging in primary coenzyme-q10-deficiency disorders. Antioxidants, 12:718, Mar 2023. URL: https://doi.org/10.3390/antiox12030718, doi:10.3390/antiox12030718. This article has 17 citations.
(munch2023neuroimaginginprimary pages 3-4): Juliane Münch, Jannik Prasuhn, Lucia Laugwitz, Cheuk-Wing Fung, Brian H.-Y. Chung, Marcello Bellusci, Ertan Mayatepek, Dirk Klee, and Felix Distelmaier. Neuroimaging in primary coenzyme-q10-deficiency disorders. Antioxidants, 12:718, Mar 2023. URL: https://doi.org/10.3390/antiox12030718, doi:10.3390/antiox12030718. This article has 17 citations.
(salviati2023primarycoenzymeq10b pages 5-7): L Salviati, E Trevisson, C Agosto, M Doimo, and P Navas. Primary coenzyme q10 deficiency overview. Unknown journal, 2023.
(wahedi2024clinicalfeaturesbiochemistry pages 2-3): Azizia Wahedi, Sniya Sudhakar, Amanda Lam, Jose Ignacio Rodriguez Ciancio, Philippa Mills, Paul Gissen, Alice Gardham, Jogesh Kapadia, Jane Hassell, Simon Heales, and Shamima Rahman. Clinical features, biochemistry, imaging, and treatment response in a single-center cohort with coenzyme q ₁₀ biosynthesis disorders. Dec 2024. URL: https://doi.org/10.1212/nxg.0000000000200209, doi:10.1212/nxg.0000000000200209. This article has 6 citations.
(munch2023neuroimaginginprimary pages 6-9): Juliane Münch, Jannik Prasuhn, Lucia Laugwitz, Cheuk-Wing Fung, Brian H.-Y. Chung, Marcello Bellusci, Ertan Mayatepek, Dirk Klee, and Felix Distelmaier. Neuroimaging in primary coenzyme-q10-deficiency disorders. Antioxidants, 12:718, Mar 2023. URL: https://doi.org/10.3390/antiox12030718, doi:10.3390/antiox12030718. This article has 17 citations.
(mantle2023primarycoenzymeq10 pages 2-4): David Mantle, Lauren Millichap, Jesus Castro-Marrero, and Iain P. Hargreaves. Primary coenzyme q10 deficiency: an update. Antioxidants, 12:1652, Aug 2023. URL: https://doi.org/10.3390/antiox12081652, doi:10.3390/antiox12081652. This article has 51 citations.
(hargreaves2023primarycoenzymeq10 pages 2-4): Iain Parry Hargreaves and David Mantle. Primary coenzyme q10 deficiency: an update. Unknown journal, May 2023. URL: https://doi.org/10.20944/preprints202305.1024.v1, doi:10.20944/preprints202305.1024.v1.
(hargreaves2023primarycoenzymeq10 pages 1-2): Iain Parry Hargreaves and David Mantle. Primary coenzyme q10 deficiency: an update. Unknown journal, May 2023. URL: https://doi.org/10.20944/preprints202305.1024.v1, doi:10.20944/preprints202305.1024.v1.
(munch2023neuroimaginginprimary pages 10-12): Juliane Münch, Jannik Prasuhn, Lucia Laugwitz, Cheuk-Wing Fung, Brian H.-Y. Chung, Marcello Bellusci, Ertan Mayatepek, Dirk Klee, and Felix Distelmaier. Neuroimaging in primary coenzyme-q10-deficiency disorders. Antioxidants, 12:718, Mar 2023. URL: https://doi.org/10.3390/antiox12030718, doi:10.3390/antiox12030718. This article has 17 citations.
(staiano2023biosynthesisdeficiencyand pages 1-2): Carmine Staiano, Laura García-Corzo, David Mantle, Nadia Turton, Lauren E. Millichap, Gloria Brea-Calvo, and Iain Hargreaves. Biosynthesis, deficiency, and supplementation of coenzyme q. Antioxidants, 12:1469, Jul 2023. URL: https://doi.org/10.3390/antiox12071469, doi:10.3390/antiox12071469. This article has 24 citations.
(wahedi2024clinicalfeaturesbiochemistry media 455edda8): Azizia Wahedi, Sniya Sudhakar, Amanda Lam, Jose Ignacio Rodriguez Ciancio, Philippa Mills, Paul Gissen, Alice Gardham, Jogesh Kapadia, Jane Hassell, Simon Heales, and Shamima Rahman. Clinical features, biochemistry, imaging, and treatment response in a single-center cohort with coenzyme q ₁₀ biosynthesis disorders. Dec 2024. URL: https://doi.org/10.1212/nxg.0000000000200209, doi:10.1212/nxg.0000000000200209. This article has 6 citations.
(wahedi2024clinicalfeaturesbiochemistry media 782a63c5): Azizia Wahedi, Sniya Sudhakar, Amanda Lam, Jose Ignacio Rodriguez Ciancio, Philippa Mills, Paul Gissen, Alice Gardham, Jogesh Kapadia, Jane Hassell, Simon Heales, and Shamima Rahman. Clinical features, biochemistry, imaging, and treatment response in a single-center cohort with coenzyme q ₁₀ biosynthesis disorders. Dec 2024. URL: https://doi.org/10.1212/nxg.0000000000200209, doi:10.1212/nxg.0000000000200209. This article has 6 citations.
(wahedi2024clinicalfeaturesbiochemistry media 84940300): Azizia Wahedi, Sniya Sudhakar, Amanda Lam, Jose Ignacio Rodriguez Ciancio, Philippa Mills, Paul Gissen, Alice Gardham, Jogesh Kapadia, Jane Hassell, Simon Heales, and Shamima Rahman. Clinical features, biochemistry, imaging, and treatment response in a single-center cohort with coenzyme q ₁₀ biosynthesis disorders. Dec 2024. URL: https://doi.org/10.1212/nxg.0000000000200209, doi:10.1212/nxg.0000000000200209. This article has 6 citations.
(rodriguezaguilera2017biochemicalassessmentof pages 1-3): Juan Rodríguez-Aguilera, Ana Cortés, Daniel Fernández-Ayala, and Plácido Navas. Biochemical assessment of coenzyme q10 deficiency. Journal of Clinical Medicine, 6:27, Mar 2017. URL: https://doi.org/10.3390/jcm6030027, doi:10.3390/jcm6030027. This article has 71 citations.
(hernandez‐camacho2024prenatalandprogressive pages 1-2): Juan Diego Hernández‐Camacho, Cristina Vicente‐García, Lorena Ardila‐García, Ana Padilla‐Campos, Guillermo López‐Lluch, Carlos Santos‐Ocaña, Peter S. Zammit, Jaime J. Carvajal, Plácido Navas, and Daniel J.M. Fernández‐Ayala. Prenatal and progressive coenzyme q10 administration to mitigate muscle dysfunction in mitochondrial disease. Journal of Cachexia, Sarcopenia and Muscle, 15:2402-2416, Oct 2024. URL: https://doi.org/10.1002/jcsm.13574, doi:10.1002/jcsm.13574. This article has 8 citations and is from a domain leading peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Biochemical Markers

Source YAML

References & Deep Research

Deep Research

1. Disease Information

1.1 What is the disease?

1.2 Key identifiers

1.3 Synonyms / alternative names

1.4 Evidence source type

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Major phenotype domains (with frequencies when available)

3.2 Suggested HPO terms (non-exhaustive; evidence-aligned)

3.3 Quality of life impact

4. Genetic / Molecular Information

4.1 Causal genes (core list)

4.2 Pathogenic variants

4.3 Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Key concepts: CoQ10 functions

6.2 Causal chain (trigger → molecular dysfunction → tissue injury → clinical phenotype)

6.3 Cellular processes and pathways (suggested ontology terms)

7. Anatomical Structures Affected

7.1 Organ systems

7.2 Suggested UBERON terms (ontology suggestions)

7.3 Subcellular localization

8. Temporal Development

8.1 Onset

8.2 Progression

9. Inheritance and Population

9.1 Inheritance

9.2 Epidemiology

9.3 Demographics / geographic distribution

10. Diagnostics

10.1 Biochemical testing

10.2 Genetic testing

10.3 Imaging

10.4 Differential diagnosis

11. Outcome / Prognosis

11.1 Prognosis statistics (recent)

11.2 Prognostic factors

12. Treatment

12.1 Pharmacotherapy (current standard)

12.2 Treatment monitoring / real-world implementation

12.3 Clinical trials landscape

12.4 Suggested MAXO terms

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms and Experimental Systems

15.1 Yeast and in vitro systems

15.2 Mouse models (examples explicitly mentioned)

Recent developments and expert synthesis (2023–2024 emphasis)

Limitations of this report (evidence availability)

Key URLs (most recent/authoritative in this run)

Artifacts